Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
SUSPENDED
NCT03546335
PHASE1

Zr-89 Cimzia PET Imaging Rheumatoid Arthritis

Sponsor: Robert Flavell, MD, PhD

View on ClinicalTrials.gov

Summary

This is a single center exploratory imaging study investigating the initial application of zirconium-89 Deferoxamine B Certolizumab pegol (89Zr-DFO-CZP) PET in patients with rheumatoid arthritis. Patients with active symptoms of RA or signs on physical exam will be invited to participate for PET imaging.

Official title: Zirconium-89 Certolizumab PET Imaging in Patients With Rheumatoid Arthritis

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2018-10-01

Completion Date

2029-03-31

Last Updated

2026-05-04

Healthy Volunteers

No

Interventions

DRUG

89Zr-DFO-CZP

89Zr-DFO-Certolizumab pegol (89Zr-DFO-CZP) is a radiopharmaceutical imaging agent that will be produced under Current Good Manufacturing Practice (CGMP) regulations in the Department of Radiology and Biomedical Imaging Radiopharmaceutical Facility at University of California, San Francisco (UCSF).

Locations (1)

University of California, San Francisco

San Francisco, California, United States